Lumiquin

Hydroquinone, tretinoin, fluocinolone acetonide.

Each gram of cream contains: Hydroquinone 40 mg, Tretinoin 0.5 mg, Fluocinolone acetonide 0.1 mg.

LUMIQUIN cream contains Hydroquinone, as a depigmenting agent, and may interrupt one or more steps in the tyrosine-tyrosinase pathway of melanin synthesis, Tretinoin as a keratolytic agent, and Fluocinolone acetonide as an anti-inflammatory agent. However, the mechanism of action of the active ingredients in LUMIQUIN cream in the treatment of melasma is unknown.

Indicated for the short-term treatment of moderate to severe melasma of the face, in the presence of measures for sun avoidance, including the use of sunscreens.
LUMIQUIN cream contains corticosteroid, retinoid, and depigmenting agent, is not indicated for the maintenance treatment of melasma.
The safety and efficacy of LUMIQUIN cream in the treatment of hyperpigmentation conditions other than melasma of the face have not been studied.

Apply a thin film of the cream to the areas of melasma once daily at night. at least 30 minutes before bedtime, alter cleansing the face.
Kept away from the eyes, nose, or angles of the mouth.
Usage is not recommended for more than 8 weeks, or as directed by your medical physician. Do not use occlusive dressing.
If local irritation persists or becomes severe, application of the medication should be discontinued, and contact your physician.
To keep from dry condition, patients may use moisturizers and/or cosmetics every morning after cleansing the face.
Avoid sun exposure and use a sunscreen with SPF 30 or greater to protect the medicated area from the sun exposure.
Therapeutics effects may be observed as early as 4 weeks. If no change occurs, use of the medication should be discontinued.

Patients with a history of hypersensitivity, allergy, or intolerance to this product or any of its components.

LUMIQUIN cream, a combination drug product containing corticosteroid, retinoid, and depigmenting agent, is not indicated for the maintenance treatment of melasma. After achieving control with LUMIQUIN cream, it can be continued with other treatment as a replacement therapy of LUMIOUIN cream, because melasma can be happened again alter discontinue the usage of LUMIQUIN cream.
Patients need to avoid sunlight exposure, use sunscreen with SPF 30 or greater, wear protective covering (such as umbrella or hat), and change to non-hormonal forms of birth control, if hormonal methods are used.
LUMIQUIN cream contains Sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible people.
LUMIQUIN cream contains Hydroquinone, which may produce exogenous ochronosis, a gradual blue-black darkening of the skin, whose occurrence should prompt discontinuation of therapy. The majority of patients developing this condition are Black, but it may also occur in Caucasians and Hispanics.
The safety and efficacy of LUMIQUIN cream in patients of skin types V and VI have not been studied.
The safety and efficacy of LUMIQUIN cream in pregnant women and nursing mothers have not been established.
Exposure to sunlight or ultraviolet light should be avoided. Patients who are consistently exposed to sunlight or skin irritants either through their work environment or habits should exercise particular caution. Sunscreen with SPF 30 or greater and protective covering (such as hat) over the treated areas should be used. Sunscreen use is an essential aspect of melasma therapy, as even minimal sunlight sustains melanocytic activity.
Weather extremes, such as heat or cold, may be irritating to patients treated with LUMIQUIN cream. Because of the drying effect of this medication, a moisturizer may be applied to the face in the morning alter washing.
Application of LUMIQUIN cream should be kept away from the eyes, nose, or angles of the mouth, because the mucosa is more sensitive. If local irritation persists or becomes severe, application of the medication should be discontinued, and consult the physician. Allergic contact dermatitis, blistering, crusting, and severe burning or swelling of the skin and irritation of the mucous membranes of the eyes, nose, and mouth require medical attention.
Carcinogenesis, mutagenesis, impairment of fertility: Studies of Hydroquinone in animals have demonstrated some evidence of carcinogenicity. The carcinogenic potential of Hydroquinone in human is unknown. Studies in hairless albino mice suggest that concurrent exposure to Tretinoin may enhance the tumorigenic potential. Mutagenicity studies were not conducted with this combination of active ingredients. Published studies have demonstrated that Hydroquinone is a mutagen and a clastogen.
Use in Pregnancy: Teratogenic effects: LUMIQUIN cream contains the teratogen, Tretinoin, which may cause embryo-fetal death, altered fetal growth, congenital malformations, and potential neurologic deficits. There are no adequate and well controlled studies in pregnant women.
LUMIQUIN cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pregnancy: Teratogenic effects: LUMIQUIN cream contains the teratogen, Tretinoin, which may cause embryo-fetal death, altered fetal growth, congenital malformations, and potential neurologic deficits. There are no adequate and well controlled studies in pregnant women.
LUMIQUIN cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Local irritation, such as dryness, reddening, mild burning sensation, and peeling. If hypersensitivity reaction or chemical irritation occur, the use of the medication should be discontinued.

Abrasive soaps or cleansers, soaps and cosmetics with drying effects, products with high concentration of alcohol and astringent.
Cosmetic which can cause photosensitizing.

Store below 30 °C, tightly closed, and protect from light.

Other Dermatologicals

D11AX - Other dermatologicals ; Used in the treatment of dermatological diseases.

G